Findings from a subanalysis of a large international study demonstrated similar efficacy of SGLT2 inhibitors for reducing body mass index (BMI) among patients with minor obesity in Asian, European, and American populations [11,12]. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.